KLK3 and prostate carcinoma: This may reflect the fact that all patients undergoing brachytherapy have a risk of intraoperative hematogenous spillage of prostate cancer cells, irrespective of use of neoadjuvant hormonal therapy, type of brachytherapy, age, PSA at diagnosis, Gleason score, clinical stage, and biopsy positive core rates.